Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 565-572

  Seksik, Philippe ^a   Mary, Jean Yves ^b   Beaugerie, Laurent ^a   Lémann, Marc ^c   Colombel, Jean Frederic ^d   Vernier Massouille, Gwenolla ^d   Cosnes, Jacques ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

azathioprine; hepatic nodular hyperplasia; inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ADULT; ARTICLE; CROHN DISEASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; INTESTINE PERFORATION; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NODULAR REGENERATIVE HYPERPLASIA; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMALL INTESTINE RESECTION; TREATMENT DURATION; ULCERATIVE COLITIS; VOMITING;

ADULT; AZATHIOPRINE; FEMALE; FOCAL NODULAR HYPERPLASIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77957192395     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21330     Document Type: Article

References (29)

1. Steiner PE,. Nodular regenerative hyperplasia of the liver. Am J Pathol. 1959; 35: 943-953.
2. Arvanitaki M, Adler M,. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastroenterology. 2001; 48: 1425-1429.
3. Stromeyer FW, Ishak KG,. Nodular transformation (nodular "regenerative" hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol. 1981; 12: 60-71.
4. Naber AH, Van Haelst U, Yap SH,. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol. 1991; 12: 94-99.
5. Wanless IR, Godwin TA, Allen F, et al. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore). 1980; 59: 367-379.
6. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003; 125: 298-303.
7. de Boer NK, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006; 73: 25-31.
8. de Boer NK, Zondervan PE, Gilissen LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis. 2008; 40: 108-113.
9. Daniel F, Cadranel JF, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol. 2005; 29: 600-603.
10. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007; 56: 1404-1409. (Pubitemid 47517834)
11. Mantel N,. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
13. Byar D,. Identification of prognostic factors. In:, Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trials, methods and practice. Oxford: Oxford medical publications; 1988.
14. Altman DG, De Stavola BL,. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med. 1994; 13: 301-341.
15. Wanless IR,. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11: 787-797.
16. Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996; 28: 195-204.
17. Blanc JF, Bernard PH, Le Bail B, et al. [Vascular pathology of the portal vein distal branches: a rare cause of liver transplantation and a protean clinical presentation.] Gastroenterol Clin Biol. 2000; 24: 667-670.
18. De Boer NK, Tuynman H, Bloemena E, et al. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol. 2008; 43: 604-608.
19. Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003; 123: 100-102.
20. DeLeve LD, Valla DC, Garcia-Tsao G,. Vascular disorders of the liver. Hepatology. 2009; 49: 1729-1764.
21. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology. 1986; 90: 446-454.
22. Stojiljkovic V, Todorovic A, Radlovic N, et al. Antioxidant enzymes, glutathione and lipid peroxidation in peripheral blood of children affected by coeliac disease. Ann Clin Biochem. 2007; 44: 537-543.
23. Jackson AA,. Glutathione in kwashiorkor. Am J Clin Nutr. 2002; 76: 495-496.
24. Buchel O, Roskams T, Van Damme B, et al. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut. 2005; 54: 1021-1023.
25. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005; 43: 303-309.
26. Zech CJ, Seiderer J, Reinisch W, et al. Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol. 2007; 17: 1898-1905.
27. Lennard-Jones JE,. Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease. Dig Dis Sci. 1981; 26: 364-368.
28. Rutgeerts P, Baert F,. New strategies in the management of inflammatory bowel disease. Acta Clin Belg. 1999; 54: 274-280.
29. Present DH,. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am. 1989; 18: 57-71.